IntelGenx (TSXV:IGX; OTCQB:IGXT) received a cannabis micro-processing license from Health Canada under the Cannabis Act and Cannabis Regulations for the company’s Montreal, Quebec facility.
“Receipt of this cannabis micro-processing license is an important milestone, particularly because it enables us to commence working towards commercial production of our cannabis-infused VersaFilm, which we believe offers a discrete, precise and convenient option for adult-use and medical cannabis consumers,” Dr. Horst Zerbe, CEO of IntelGenx, said in a statement.
“In view of current market conditions, we are working with our co-development partner and reviewing various options with the goal of aligning on the timing of a potential commercial launch,” he added.
